Skip to main content
. Author manuscript; available in PMC: 2018 May 14.
Published in final edited form as: Clin Cancer Res. 2017 Dec 20;24(6):1389–1401. doi: 10.1158/1078-0432.CCR-17-1958

Figure 4.

Figure 4

Pretreatment with 5-azacytidine increases global 5-hmC levels and platinum sensitivity. A, 5-hmC immunoblot and quantification of 5-hmC levels in A2780Res, CaOV3, OVCAR4, OVSAHO tumor lines treated for 72 hours with 5-azacytidine (5-aza). Methylene blue staining was used as a DNA loading control. Pretreatment with 5-aza significantly increases 5-hmC levels at all concentrations when compared with untreated (NT) controls in the tested cancer cell lines (*, P < 0.05; **, P < 0.01; ***, P < 0.001). B, The platinum sensitivity of ovarian cancer cell lines increases following pretreatment with 5-aza as shown by MTT analysis. Tumor lines, which were treated for 72 hours with 5, 10, or 20 μmol/L 5-aza followed by CDDP therapy, show statistically significant increases in CDDP IC50 values (*, P < 0.05; **, P < 0.01; ***, P < 0.001).